Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-10-26
2010-11-09
Gussow, Anne M. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387300, C530S388100, C424S130100, C424S133100, C424S134100
Reexamination Certificate
active
07829674
ABSTRACT:
The present invention relates to anti-S1P agents, for example, humanized monoclonal antibodies, and their uses for detection of S1P or for treatment of diseases and conditions associated with S1P.
REFERENCES:
patent: 4150949 (1979-04-01), Smith
patent: 4816450 (1989-03-01), Bell et al.
patent: 4937232 (1990-06-01), Bell et al.
patent: 5079263 (1992-01-01), Zeeck et al.
patent: 5137919 (1992-08-01), Igarashi et al.
patent: 5151360 (1992-09-01), Handa et al.
patent: 5248824 (1993-09-01), Igrashi et al.
patent: 5260288 (1993-11-01), Igarashi et al.
patent: 5331014 (1994-07-01), Kimura et al.
patent: 5369030 (1994-11-01), Hannun et al.
patent: 5391800 (1995-02-01), Igrashi et al.
patent: 5430160 (1995-07-01), Holton
patent: 5444087 (1995-08-01), Patel et al.
patent: 5585476 (1996-12-01), MacLennan et al.
patent: 5627171 (1997-05-01), Park et al.
patent: 5663404 (1997-09-01), Igarashi et al.
patent: 5677288 (1997-10-01), Marangos
patent: 5677337 (1997-10-01), Wei et al.
patent: 5851782 (1998-12-01), Hannun et al.
patent: 5877167 (1999-03-01), Igarashi et al.
patent: 5919687 (1999-07-01), Chatterjee
patent: 5929039 (1999-07-01), Woodcock et al.
patent: 5989803 (1999-11-01), Tabas et al.
patent: 6051598 (2000-04-01), Shayman et al.
patent: 6057126 (2000-05-01), Munroe et al.
patent: 6130067 (2000-10-01), Tsui
patent: 6140060 (2000-10-01), Chun et al.
patent: 6187562 (2001-02-01), Duckworth et al.
patent: 6210976 (2001-04-01), Sabbadini
patent: 6284798 (2001-09-01), Amtmann et al.
patent: 6306911 (2001-10-01), Wachter et al.
patent: 6323201 (2001-11-01), Carson et al.
patent: 6342221 (2002-01-01), Thorpe et al.
patent: 6352844 (2002-03-01), Maurer et al.
patent: 6423527 (2002-07-01), Saba et al.
patent: 6534322 (2003-03-01), Sabbadini
patent: 6534323 (2003-03-01), Sabbadini
patent: 6610835 (2003-08-01), Liotta et al.
patent: 6613322 (2003-09-01), Tabas et al.
patent: 6649362 (2003-11-01), Gamble et al.
patent: 6858383 (2005-02-01), Sabbadini
patent: 6881546 (2005-04-01), Sabbadini
patent: 7169390 (2007-01-01), Sabbadini
patent: 2001/0041688 (2001-11-01), Waeber et al.
patent: 2002/0150582 (2002-10-01), Friedrichs et al.
patent: 2003/0125533 (2003-07-01), Kossida et al.
patent: 2003/0219782 (2003-11-01), Saba et al.
patent: 2007/0148168 (2007-06-01), Sabbadini et al.
patent: 0173648 (1986-03-01), None
patent: 0173663 (1986-03-01), None
patent: 09-110722 (1987-04-01), None
patent: 2000-293181 (2000-10-01), None
patent: WO 97/44019 (1997-11-01), None
patent: WO 98/03529 (1998-01-01), None
patent: WO 98/28445 (1998-07-01), None
patent: WO 98/40349 (1998-09-01), None
patent: WO 98/57179 (1998-12-01), None
patent: WO 99/07855 (1999-02-01), None
patent: WO 99/12890 (1999-03-01), None
patent: WO 99/16888 (1999-04-01), None
patent: WO 99/33972 (1999-07-01), None
patent: WO 99/38983 (1999-08-01), None
patent: WO 99/41265 (1999-08-01), None
patent: WO 99/41266 (1999-08-01), None
patent: WO 99/46277 (1999-09-01), None
patent: WO 99/61581 (1999-12-01), None
patent: WO 00/00593 (2000-01-01), None
patent: WO 00/21919 (2000-04-01), None
patent: WO 00/40262 (2000-07-01), None
patent: WO 00/52173 (2000-09-01), None
patent: WO 00/56135 (2000-09-01), None
patent: WO 00/58448 (2000-10-01), None
patent: WO 00/58491 (2000-10-01), None
patent: WO 00/59517 (2000-10-01), None
patent: WO 00/70028 (2000-11-01), None
patent: WO 00/72833 (2000-12-01), None
patent: WO 01/04108 (2001-01-01), None
patent: WO 01/04139 (2001-01-01), None
patent: WO 01/07418 (2001-02-01), None
patent: WO 01/31029 (2001-05-01), None
patent: WO 01/38295 (2001-05-01), None
patent: WO 01/55410 (2001-08-01), None
patent: WO 01/57057 (2001-08-01), None
patent: WO 01/60990 (2001-08-01), None
patent: WO 01/71045 (2001-09-01), None
patent: WO 01/72701 (2001-10-01), None
patent: WO 01/80903 (2001-11-01), None
patent: WO 01/85953 (2001-11-01), None
Skolnick and Fetrow. From genes to protein structure and function: novel applications of computational approaches in the genomic era. Trends in Biotechnology, 2000. vol. 18, pp. 34-39.
Burgess, Shaheen, Ravera, Jaye, Donohue, and Winkles. Possible dissociation of the heparin-binding and mitogenic activities of heparin-binding (acidic fibroblast) growth factor 1 from its receptor binding activities by site-directed mutagenesis of a single lysine residue. Journal of Cell Biology, 1990. vol. 111, pp. 2129-2138.
Lazar, Watanabe, Dalton, and Sporn. Transforming growth factor a: mutation of aspartic acid 47 and leucine 48 results in different biological activities. Molecular and Cellular Biology, 1988. vol. 8, pp. 1247-1252.
Holm, Jafari, and Sundstrom. Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. Molecular Immunology, 2007. vol. 44, pp. 1075-1084.
Chen, Weismann, Fuh, Li, Christinger, Mc Kay, De Vos, and Lowman. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. Journal of Molecular Biology, 1999. vol. 293, pp. 865-881.
Rudikoff, Giusti, Cook, and Scharff. Single amino acid substitution altering antigen binding specificity. Proceedings of the National Academy of Sciences, 1982. vol. 79, pp. 1979-1983.
Mac Callum, Martin, and Thornton. Antibody-antigen interactions: contact analysis and binding site topography. Journal of Molecular Biology, 1996. vol. 262, pp. 732-745.
De Pascalis, Iwahashi, Tamura, Padlan, Gonzales, Santos, Giuliano, Schuck, Schlom, and Kashmiri. Grafting of “abbreviated” complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody. Journal of Immunology, 2002. vol. 169, pp. 3076-3084.
Casset, Roux, Mouchet, Bes, Chardes, Granier, Mani, Pugniere, Laune, Pau, Kaczorek, Lahana, and Rees. A peptide mimetic of an anti-CD4 monoclonal antibody by rational design. Biochemical and Biophysical Research Communications, 2003. vol. 307, pp. 198-205.
Vajdos, Adams, Breece, Presta, De Vos, and Sidhu. Comprehensive functional maps of the antigen-binding site of an anti-ErbB2 antibody obtained with shotgun scanning mutagenesis. Journal of Molecular Biology, 2002. vol. 320, pp. 415-428.
Wu, Nie, Huse, and Watkins. Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues. Journal of Molecular Biology, 1999. vol. 294, pp. 151-162.
Abe et al., “Structural and stereochemical studies of potent inhibitors and glucosylceramide synthase and tumor cell growth,”J. Lipid Res.36(3):611-621 (1995).
Abe et al., “Glycosphingolipid depletion in Fabry disease lymphoblasts with potent inhibitors of glucosylceramide synthase,”Kidney Int.57(2):446-454 (2000).
Abe et al., “Use of Sulfobutyl Ether-Cyclodextrin as a Vehicle for D-threo-1-Phenyl-2-decanoylamino-3-morpholinopropanol-Related Glucosylceramide Synthase Inhibitors,”Anal. Biochem.287(2):344-347 (2000).
Ambati, “Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies,”Surv. Ophthalmol.48(3):257-293 (2003) (Abstract Only).
An et al., “Identification of cDNAs encoding two G protein-coupled receptors for lysosphingolipids,”FEBS Letts.417(3):279-282 (1997).
An et al., “Characterization of a Novel Subtype of Human G Protein-coupled Receptor for Lysophosphotatidic Acid,”J. Biol. Chem.273(14):7906-7910 (1998).
An et al., “Sphingosine 1-phosphate-induced cell proliferation, survival, and related signaling events mediated by G protein-coupled receptors Edg3 and Edg5,”J. Biol. Chem.275(1):288-296 (2000).
Ancellin et al., “Extracelluar export of sphingosine kinase-1 enzyme: Sphingosine 1 phosphate generation and the induction of angiogenic vascular maturation,”J. Biol. Chem.277(8):6667-6675 (2001).
Andrieu-Abadie et al., “L-camitine prevents doxorubicin-induced apoptosis of cardiac myocytes: role of inhibition of ceramide generation,”FASEB J.13(12):1501-1510 (1999).
Arenz et al., “Synthese des ersten selektiven irreverilben I
Garland William A.
Hansen Genevieve
Jones Steven Tarran
Sabbadini Roger A.
Williams David Gareth
BioTechnology Law Group
Chambers Daniel M.
Gussow Anne M.
Lpath, Inc.
LandOfFree
Compositions and methods for binding sphingosine-1-phosphate does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for binding sphingosine-1-phosphate, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for binding sphingosine-1-phosphate will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4190846